Suggested remit: To appraise the clinical and cost effectiveness of tucatinib with trastuzumab and capecitabine within its marketing authorisation for treating HER2-positive unresectable or metastatic advanced breast cancer after 2 or more anti-HER2 therapies.
Status In progress
Process STA 2018
ID number 3828

Provisional Schedule

Committee meeting: 2 07 December 2021
Expected publication 22 December 2021

Project Team

Project lead Shonagh D'Sylva

Email enquiries


Companies sponsors Seagen Inc (tucatinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Care & Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies Amgen (trastuzumab)
  Pfizer (trastuzumab)
  Pierre Fabre (vinorelbine)
  Roche (capecitabine, trastuzumab)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
26 October 2021 - 16 November 2021 Appraisal consultation
05 October 2021 Committee meeting: 1
12 February 2021 Invitation to participate
09 November 2020 - 07 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 August 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance